Treatment options in anthracycline and/or taxane pretreated patients with metastatic breast cancer

Onkologie

Volumn 35, Issue 9, 2012, Pages 476-478

  Pugliano, Lina ^a,b   De Azambuja, Evandro ^a,b  

^a Department of Medicine ^*  (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; ERIBULIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; IXABEPILONE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE;

ADJUVANT THERAPY; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDITORIAL; HUMAN; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LEUKOPENIA;

EID: 84866850496     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000342209     Document Type: Editorial

References (29)

1. O'Shaughnessy J: Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10(suppl 3):20-29.
2. Ruiterkamp J, Ernst MF, de Munck L, van der Heiden-van der Loo M, Bastiaannet E, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC VA: Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands. Breast Cancer Res Treat 2011;28:495-503.
3. Schippert C, Warm M, Blohmer JU, du Bois A, Lück HJ: Mitomycin C in combination with vinorelbine in anthracycline and/or taxane-pretreated patients with metastatic breast cancer. Onkologie 2012;35: DOI: 10.1159/000341839.
4. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G: A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 2000;82:529-534.
5. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Van't Veer L, Viale G, Krop I, Winer E: 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (Edinburgh, Scotland) 2012; DOI: 10.1016/j. breast.2012.03.003
6. Ershler WB: Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006;11:325-335.
7. Jara-Sánchez C, Martín M, García-Sáenz JA, Barnada A, Fernández-Aramburo A, López-Vega JM, Pelegrí A, Alba E, Casado A: Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group. Clin Breast Cancer 2003;3:399-404.
8. Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M: Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline-and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast (Edinburgh, Scotland) 2008;17:180-185.
9. Papaldo P, Fabi A, Ferretti G, Mottolese M, Cianciulli AM, Di Cocco B, Pino MS, Carlini P, Di Cosimo S, Sacchi I, Sperduti I, Nardoni C, Cognetti F: A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 2006;17:630-636.
10. Seo HY, Lee HJ, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Lee ES, Kim YH, Kim JS, Seo JH: Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer. Invest New Drugs 2011;29:360-365.
11. Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T, Tokuda Y, Mitsuyama,S, Kimura M, Kobayashi T, Tamura M, Tabei T, Shin E, Nishimura R, Ohno S, Takashima S: Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol 2005;35:310-315.
12. Udom DI, Vigushin DM, Linardou H, Graham H, Palmieri C, Coombes RC: Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000;36:177-182.
13. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M: Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267-2272.
14. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA:Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-1400.
15. Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, MoralesVasquez F, Rodríguez C, Adrover E, Mel JR: Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously 431. treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219-225.
16. Günel N, Akçali Z, Yamaç D, Onuk E, Yilmaz E, Bayram O, Tekin E, Co?kun U: Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori 2012;86:283-285.
17. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L: Phase II study of vinorelbine with protracted fluorouracil infusion as a second-or thirdline approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 2000;18:3370-3377.
18. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves, C: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-923.
19. Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O'Shaughnessy JA: Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-856.
20. Thomas ES, Gomez HL, Li RK, Chung H-C, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-5217.
21. Awada A, Zhao C, Hannah AL, Perez EA: The BEACON Study (BrEAst Cancer Outcomes With NKTR-102): A phase 3 open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane and capecitabine. San Antonio Breast Cancer Conference. 2011, Abstract #OT3-01-07.
22. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane database of systematic reviews (Online) 2009;CD003372.
23. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. JNCI 2009;101:1174-81.
24. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ: Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
25. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan, A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Eng J Med 2006;355:2733-43.
26. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
27. Scheithauer W, Kornek G, Haider K, Kwasny W, Schenk T, Pirker R, Depisch D: Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. Breast Cancer Res Treat 1993;26:49-53.
28. Vici P, Di Lauro L, Carpano S, Amodio A, Pignatti F, Casali A, Conti F, Lopez M: Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer. Oncology 2012;53:16-18.
29. Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Müller C, Seeber S, Kanz L, Bokemeyer C: Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs 1998;9:427-431.